{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:10:42Z","timestamp":1789726242881,"version":"4.0.1"},"reference-count":127,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>This is a comprehensive review of the literature on drug interactions (DIs) between atypical antipsychotics and anti-infective agents that focuses on those DIs with the potential to be clinically relevant and classifies them as pharmacokinetic (PK) or pharmacodynamic (PD) DIs. PubMed searches were conducted for each of the atypical antipsychotics and most commonly used anti-infective agents (13 atypical antipsychotics by 61 anti-infective agents\/classes leading to 793 individual searches). Additional relevant articles were obtained from citations and from prior review articles written by the authors. Based on prior DI articles and our current understanding of PK and PD mechanism, we developed tables with practical recommendations for clinicians for: antibiotic DIs, antitubercular DIs, antifungal DIs, antiviral DIs, and other anti-infective DIs. Another table reflects that in clinical practice, DIs between atypical antipsychotics and anti-infective agents occur in patients also suffering an infection that may also influence the PK and PD mechanisms of both drugs (the atypical antipsychotic and the anti-infective agent(s)). These tables reflect the currently available literature and our current knowledge of the field and will need to be updated as new DI information becomes available.<\/jats:p>","DOI":"10.3390\/ph13120439","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T20:25:49Z","timestamp":1606940749000},"page":"439","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Clinically Relevant Interactions between Atypical Antipsychotics and Anti-Infective Agents"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2509-7449","authenticated-orcid":false,"given":"Edoardo","family":"Spina","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2019-4696","authenticated-orcid":false,"given":"Maria Antonietta","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8345-8679","authenticated-orcid":false,"given":"Giuseppe","family":"Cicala","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"de Leon","sequence":"additional","affiliation":[{"name":"Mental Health Research Center at Eastern State Hospital, University of Kentucky, Lexington, KY 40511-1269, USA"},{"name":"Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, University of Granada, 18011 Granada, Spain"},{"name":"Biomedical Research Centre in Mental Health Net (CIBERSAM), Santiago Apostol Hospital, University of the Basque Country, 01004 Vitoria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Spina, E., and Italiano, D. (2015). Drug interactions. Treatment of Epilepsy, Wiley-Blackwell Publishing Ltd.","DOI":"10.1002\/9781118936979.ch25"},{"key":"ref_2","unstructured":"Stahl, S.M. (2013). Antipsychotic agents. Stahl\u2019s Essential Psychopharmacology, Cambridge University Press."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1517\/17425255.2012.660918","article-title":"Interactions between antiepileptics and second-generation antipsychotics","volume":"8","author":"Santoro","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1517\/17425255.2014.885504","article-title":"Clinically relevant interactions between newer antidepressants and second-generation antipsychotics","volume":"10","author":"Spina","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2165\/00003088-199325060-00005","article-title":"Pharmacokinetic Drug Interactions with Antimicrobial Agents","volume":"25","author":"Gillum","year":"1993","journal-title":"Clin. Pharmacokinet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0002-9343(98)00408-2","article-title":"Drug interactions and anti-infective therapies","volume":"106","author":"Gregg","year":"1999","journal-title":"Am. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000086921","article-title":"Interactions of anti-infectives: A review","volume":"51","author":"Barcia","year":"2005","journal-title":"Chemotherapy"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","article-title":"Metabolic drug interactions with newer antipsychotics: A comparative review","volume":"100","author":"Spina","year":"2007","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s40263-013-0114-6","article-title":"Clinically significant drug interactions with atypical antipsychotics","volume":"27","author":"Kennedy","year":"2013","journal-title":"CNS Drugs"},{"key":"ref_10","first-page":"1507","article-title":"Macrolide\u2014Induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: An update focused on clarithromycin, azithromycin and dirithromycin","volume":"29","author":"Westphal","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1128\/AAC.36.5.942","article-title":"Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro","volume":"36","author":"Fuhr","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Alffenaar","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00002018-200225020-00005","article-title":"Clinically significant interactions with drugs used in the treatment of tuberculosis","volume":"25","author":"Yew","year":"2002","journal-title":"Drug Saf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1503\/cmaj.131626","article-title":"Managing drug interactions in HIV-infected adults with comorbid illness","volume":"187","author":"Hughes","year":"2015","journal-title":"CMAJ"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2012.747952","article-title":"Update on rifampin, rifabutin, and rifapentine drug interactions","volume":"29","author":"Baciewicz","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2217\/pgs.11.55","article-title":"Relationship between P-glycoprotein and second-generation antipsychotics","volume":"12","author":"Moons","year":"2011","journal-title":"Pharmacogenomics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40263-012-0008-z","article-title":"Psychotropic drug-drug interactions involving P-glycoprotein","volume":"26","author":"Akamine","year":"2012","journal-title":"CNS Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s40263-014-0196-9","article-title":"QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: A comprehensive review","volume":"28","author":"Hasnain","year":"2014","journal-title":"CNS Drugs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/jac\/dkw591","article-title":"Antimicrobials and QT prolongation","volume":"72","author":"Mason","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2337\/dc06-1075","article-title":"Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: Associations with insulin resistance, disturbed body fat compartmental","volume":"30","author":"Samaras","year":"2007","journal-title":"Diabetes Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/14740338.2019.1644317","article-title":"Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment","volume":"18","author":"Lagathu","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3803\/EnM.2019.34.2.95","article-title":"Human immunodeficiency virus infection and the endocrine system","volume":"34","author":"Zaid","year":"2019","journal-title":"Endocrinol. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40261-017-0498-z","article-title":"Neuropsychiatric Effects of Antimicrobial Agents","volume":"37","author":"Zareifopoulos","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40263-019-00649-9","article-title":"Neurological and Psychiatric Adverse Effects of Antimicrobials","volume":"33","author":"Bangert","year":"2019","journal-title":"CNS Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.seizure.2020.08.012","article-title":"Antibiotic-induced epileptic seizures: Mechanisms of action and clinical considerations","volume":"81","author":"Wanleenuwat","year":"2020","journal-title":"Seizure"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.2174\/1381612823666170809102258","article-title":"de Potentially Clinically Relevant Pharmacodynamic Interactions Between Antiepileptic Drugs and Psychotropic Drugs: An Update","volume":"23","author":"Spina","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1176\/ajp.151.12.1840b","article-title":"Seizure following addition of erythromycin to clozapine treatment","volume":"151","author":"Funderburg","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/archinte.1996.00440060103013","article-title":"Erythromycin-induced clozapine toxic reaction","volume":"156","author":"Cohen","year":"1996","journal-title":"Arch. Intern. Med."},{"key":"ref_32","first-page":"1144","article-title":"Respiratory infections rather than antibiotics may increase clozapine levels: A critical review of the literature","volume":"65","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s002280050621","article-title":"Absence of interaction between erythromycin and a single dose of clozapine","volume":"55","author":"Spigset","year":"1999","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"812","DOI":"10.4088\/JCP.v62n1010","article-title":"Repeated ingestion of grapefruit juice does not alter clozapine\u2019s steady-state plasma levels, effectiveness, and tolerability","volume":"62","author":"Lane","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00228-004-0853-x","article-title":"De Effect of erythromycin on metabolism of quetiapine in Chinese suffering from schizophrenia","volume":"60","author":"Li","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1055\/s-0028-1082071","article-title":"Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: Confirmation of the pharmacokinetic interaction potential of quetiapine","volume":"41","author":"Bewig","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1164\/rccm.201402-0385CI","article-title":"Macrolide antibiotics and the risk of cardiac arrhythmias","volume":"189","author":"Albert","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"bcr2016217421","DOI":"10.1136\/bcr-2016-217421","article-title":"Clarithromycin-induced akathisia: A class effect of macrolides?","volume":"2016","author":"Gbinigie","year":"2016","journal-title":"BMJ Case Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jsps.2015.02.012","article-title":"Akathisia with Erythromycin: Induced or precipitated?","volume":"23","author":"Sachdeva","year":"2015","journal-title":"Saudi Pharm. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1176\/ajp.154.6.881a","article-title":"Fluoroquinolone inhibition of clozapine metabolism","volume":"154","author":"Markowitz","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s002280000192","article-title":"Ciprofloxacin increases serum clozapine and N-desmethylclozapine: A study in patients with schizophrenia","volume":"56","author":"Raaska","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2165\/00002018-200124130-00002","article-title":"Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions","volume":"24","author":"Balant","year":"2001","journal-title":"Drug Saf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1176\/appi.psy.49.2.176","article-title":"Clozapine toxicity in smoking cessation and with ciprofloxacin","volume":"49","author":"Brownlowe","year":"2008","journal-title":"Psychosomatics"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/0044011-200929010-00006","article-title":"Ciprofloxacin strongly inhibits clozapine metabolism: Two case reports","volume":"29","author":"Brouwers","year":"2009","journal-title":"Clin. Drug Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/5606098","article-title":"Ciprofloxacin and Clozapine: A Potentially Fatal but Underappreciated Interaction","volume":"2016","author":"Meyer","year":"2016","journal-title":"Case Rep. Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1176\/appi.psy.48.2.170","article-title":"Clozapine case series","volume":"48","author":"Sandson","year":"2007","journal-title":"Psychosomatics"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00228-007-0313-5","article-title":"Interaction of clozapine and ciprofloxacin: A case report","volume":"63","author":"Sambhi","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00004714-199906000-00023","article-title":"Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration","volume":"19","author":"Markowitz","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1176\/appi.ajp.2015.15030353","article-title":"Sudden-onset dystonia in a patient taking asenapine: Interaction between ciprofloxacin and asenapine metabolism","volume":"172","author":"Ridout","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0009-9236(99)70105-0","article-title":"Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2","volume":"65","author":"Fuhr","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/j.1745-7254.2008.00908.x","article-title":"Determination of the inhibitory potential of 6 fuoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes","volume":"29","author":"Zhang","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000506355","article-title":"Around 3% of 1,300 Levels Were Elevated during Infections in a Retrospective Review of 131 Beijing Hospital In-Patients with More than 24,000 Days of Clozapine Treatment","volume":"89","author":"Ruan","year":"2020","journal-title":"Psychother. Psychosom."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000334441","article-title":"QT prolongation and Torsade de pointes induced by fluoroquinolones: Infrequent side effects from commonly used medications","volume":"120","author":"Briasoulis","year":"2011","journal-title":"Cardiology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijcard.2005.04.031","article-title":"Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine","volume":"109","author":"Letsas","year":"2006","journal-title":"Int. J. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.euroneuro.2016.11.012","article-title":"Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials","volume":"27","author":"Xiang","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11126-017-9515-x","article-title":"Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels","volume":"89","author":"Wehring","year":"2018","journal-title":"Psychiatr. Q."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/bcp.12079","article-title":"Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters","volume":"76","author":"Kiessling","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hup.1049","article-title":"No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects","volume":"24","author":"Thyssen","year":"2009","journal-title":"Hum. Psychopharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/17512433.2018.1549489","article-title":"A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone","volume":"11","author":"Schoretsanitis","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/cap.1994.4.123","article-title":"Possible Adverse Interaction between Clozapine and Ampicillin in an Adolescent with Schizophrenia","volume":"4","year":"1994","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin: Clinical relevance","volume":"42","author":"Niemi","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/clpt.2010.271","article-title":"Rifampin\u2019s acute inhibitory and chronic inductive drug interactions: Experimental and model-based approaches to drug-drug interaction trial design","volume":"89","author":"Reitman","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00004714-199802000-00015","article-title":"Pharmacokinetic interaction of clozapine and rifampicin in a forensic patient with an atypical mycobacterial infection","volume":"18","author":"Joos","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.genhosppsych.2007.02.004","article-title":"Clozapine-rifampicin interaction in a patient with pulmonary tuberculosis","volume":"29","author":"Peritogiannis","year":"2007","journal-title":"Gen. Hosp. Psychiatry"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1192\/pb.bp.115.051250","article-title":"Prescribing clozapine and rifampicin: Clinical impact of their interaction","volume":"40","author":"Parker","year":"2016","journal-title":"BJPsych Bull."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2710.2007.00811.x","article-title":"Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers","volume":"32","author":"Mahatthanatrakul","year":"2007","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/0091270007309888","article-title":"Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone","volume":"48","author":"Kim","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1515\/dmdi-2014-0005","article-title":"Lurasidone drug-drug interaction studies: A comprehensive review","volume":"29","author":"Chiu","year":"2014","journal-title":"Drug Metabol. Drug Interact."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/JCP.0b013e31819a6b53","article-title":"Increase in plasma levels of clozapine after addition of isoniazid","volume":"29","author":"Angelini","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/AAC.45.2.382-392.2001","article-title":"Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: Potent inhibition of CYP2C19 and CYP3A","volume":"45","author":"Desta","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.toxlet.2011.01.027","article-title":"Drug-drug interactions by azole antifungals: Beyond a dogma of CYP3A4 enzyme activity inhibition","volume":"202","author":"Dvorak","year":"2011","journal-title":"Toxicol. Lett."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00003088-200140070-00003","article-title":"Clinical pharmacokinetics of quetiapine: An atypical antipsychotic","volume":"40","author":"DeVane","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2125.2005.02507.x","article-title":"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics","volume":"61","author":"Grimm","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2710.2011.01271.x","article-title":"Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers","volume":"37","author":"Mahatthanatrakul","year":"2012","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1365-2125.2000.00156.x","article-title":"The effects of ketoconazole on ziprasidone pharmacokinetics\u2014A placebo-controlled crossover study in healthy volunteers","volume":"49","author":"Miceli","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s002280050440","article-title":"Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole","volume":"54","author":"Raaska","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1515\/DMDI.2001.18.3-4.263","article-title":"Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo","volume":"18","author":"Lane","year":"2001","journal-title":"Drug Metabol. Drug Interact."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.clpt.2005.07.007","article-title":"Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients","volume":"78","author":"Jung","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2133\/dmpk.20.55","article-title":"Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE","volume":"20","author":"Kubo","year":"2005","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JCP.0000000000000892","article-title":"Sustained Impairment of Lurasidone Clearance after Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety","volume":"38","author":"Greenblatt","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_81","first-page":"11","article-title":"Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports","volume":"2017","author":"Salem","year":"2017","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","article-title":"A Randomized Evaluation of the Effects of Six Antipsychotic Agents on QTc, In the Absence and Presence of Metabolic Inhibition","volume":"24","author":"Harrigan","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JCP.0b013e31827c0314","article-title":"A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and\/or CYP3A4 and a comparison to quetiapine and ziprasidone","volume":"33","author":"Potkin","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S2215-0366(15)00357-0","article-title":"Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: A systematic review and meta-analysis","volume":"3","author":"Hughes","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1345\/aph.1R343","article-title":"Pharmacotherapy considerations in patients with HIV and psychiatric disorders: Focus on antidepressants and antipsychotics","volume":"47","author":"Hill","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1017\/S109285291800113X","article-title":"Drug-drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs","volume":"24","author":"Goodlet","year":"2019","journal-title":"CNS Spectr."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1345\/aph.1A335","article-title":"Extrapyramidal symptoms with ritonavir\/indinavir plus risperidone","volume":"36","author":"Kelly","year":"2002","journal-title":"Ann. Pharmacother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00002826-200209000-00004","article-title":"Reversible coma caused by risperidone-ritonavir interaction","volume":"25","author":"Jover","year":"2002","journal-title":"Clin. Neuropharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1176\/appi.psy.41.5.453","article-title":"Neuroleptic malignant syndrome associated with use of risperidone, ritonavir, and indinavir: A case report","volume":"41","author":"Lee","year":"2000","journal-title":"Psychosomatics"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/JCP.0000000000000449","article-title":"Three cases of late onset angioedema in nursing home human immunodeficiency virus patients on ritonavir and risperidone","volume":"36","author":"Gonzalez","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1592\/phco.29.11.1386","article-title":"Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients","volume":"29","author":"Pollack","year":"2009","journal-title":"Pharmacotherapy"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/187231210790980426","article-title":"Toxicokinetic Interaction Between Quetiapine and Antiretroviral Therapy Following Quetiapine Overdose","volume":"4","author":"Hantson","year":"2010","journal-title":"Drug Metab. Lett."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1067\/mcp.2000.107507","article-title":"Quetiapine fumarate overdose: Clinical and pharmacokinetic lessons from extreme conditions","volume":"68","author":"Pollak","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1345\/aph.1P139","article-title":"Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir","volume":"44","author":"Aung","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40800-016-0027-7","article-title":"Dosing Recommendations of Aripiprazole Depot with Strong Cytochrome P450 3A4 Inhibitors: A Relapse Risk","volume":"3","author":"Hahn","year":"2016","journal-title":"Drug Saf. Case Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3851\/IMP3059","article-title":"A case of a probable drug interaction between lurasidone and atazanavir-based antiretroviral therapy","volume":"21","author":"Naccarato","year":"2016","journal-title":"Antivir. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00004714-200208000-00006","article-title":"Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers","volume":"22","author":"Penzak","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijantimicag.2014.03.014","article-title":"Effect of fosamprenavir\/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers","volume":"44","author":"Jacobs","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.pharmthera.2009.07.004","article-title":"Metabolic syndrome and associated cardiovascular risk factors in the treatment of persons with human immunodeficiency virus and severe mental illness","volume":"124","author":"Vibhakar","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1089\/aid.2011.0327","article-title":"Metabolic effects of darunavir\/ritonavir versus atazanavir\/ritonavir in treatment-naive, HIV Type 1-infected subjects over 48 weeks","volume":"28","author":"Aberg","year":"2012","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.psychres.2014.04.015","article-title":"The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk","volume":"218","author":"Ferrara","year":"2014","journal-title":"Psychiatry Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(05)17950-1","article-title":"Blockade of HERG channels by HIV protease inhibitors","volume":"365","author":"Anson","year":"2005","journal-title":"Lancet"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0033-3182(09)70866-7","article-title":"Clozapine Use in HIV-Infected Schizophrenia Patients: A Case-Based Discussion and Review","volume":"50","author":"Nejad","year":"2009","journal-title":"Psychosomatics"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1046\/j.1468-1293.2003.00142.x","article-title":"Antiretroviral therapy-induced psychosis: Case report and brief review of the literature","volume":"4","author":"Foster","year":"2003","journal-title":"HIV Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1517\/14740338.6.2.147","article-title":"Neuropsychiatric side effects of efavirenz therapy","volume":"6","author":"Arendt","year":"2007","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40263-013-0132-4","article-title":"Neurological and psychiatric adverse effects of antiretroviral drugs","volume":"28","author":"Abers","year":"2014","journal-title":"CNS Drugs"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1124\/dmd.117.079038","article-title":"The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection","volume":"46","author":"Garrison","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s40262-016-0407-2","article-title":"Drug\u2013Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications","volume":"55","author":"Smolders","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1080\/17512433.2018.1519392","article-title":"The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs","volume":"11","author":"Roncero","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2125.2000.00197.x","article-title":"Influence of hydroxychloroquine on the bioavailability of oral metoprolol","volume":"49","author":"Somer","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1046\/j.1365-2125.1996.30713.x","article-title":"Lack of effect of chloroquine on the debrisoquine (CYP2D6) and S-mephenytoin (CYP2C19) hydroxylation phenotypes","volume":"41","author":"Masimirembwa","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/9406813","article-title":"de Two Sudden and Unexpected Deaths of Patients with Schizophrenia Associated with Intramuscular Injections of Antipsychotics and Practice Guidelines to Limit the Use of High Doses of Intramuscular Antipsychotics","volume":"2016","author":"Wahidi","year":"2016","journal-title":"Case Rep. Psychiatry"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JCP.0000000000000924","article-title":"Why Do You Keep Telling Me That Drug-Drug Interactions Are Important in Psychopharmacology When i Do Not See Them in My Clinical Practice?: My Failure to Convince Clinicians","volume":"39","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2020.582348","article-title":"Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients","volume":"11","author":"Russo","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/JCP.0b013e3182491383","article-title":"Evidence-based medicine versus personalized medicine: Are they enemies?","volume":"32","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1124\/dmd.114.061093","article-title":"Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: Hypothesis with implications for personalized medicine","volume":"43","author":"Shah","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2017.03.045","article-title":"Elevated clozapine levels associated with infection: A systematic review","volume":"192","author":"Clark","year":"2018","journal-title":"Schizophr. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0278-5846(03)00148-9","article-title":"Serious respiratory infections can increase clozapine levels and contribute to side effects: A case report","volume":"27","author":"Diaz","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/0091217415610313","article-title":"Elevated risperidone serum concentrations during acute inflammation, two cases","volume":"50","author":"Hefner","year":"2015","journal-title":"Int. J. Psychiatry Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00213-015-3976-0","article-title":"Inflammation and psychotropic drugs: The relationship between C-reactive protein and antipsychotic drug levels","volume":"233","author":"Hefner","year":"2016","journal-title":"Psychopharmacology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/17425255.2016.1154043","article-title":"Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics","volume":"12","author":"Spina","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1001\/archinte.167.16.1752","article-title":"Serious adverse drug events reported to the Food and Drug Administration, 1998\u20132005","volume":"167","author":"Moore","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/schbul\/sbz093","article-title":"Data from the World Health Organization\u2019s Pharmacovigilance Database Supports the Prominent Role of Pneumonia in Mortality Associated with Clozapine Adverse Drug Reactions","volume":"46","author":"Sanz","year":"2020","journal-title":"Schizophr. Bull."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/wps.20707","article-title":"Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics","volume":"19","author":"Sanz","year":"2020","journal-title":"World Psychiatry"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/acps.13184","article-title":"Pneumonia risk: Approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia","volume":"142","author":"Rohde","year":"2020","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/17512433.2019.1577134","article-title":"A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults","volume":"12","author":"Cicala","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/schbul\/sbaa070","article-title":"COVID-19 Infection May Cause Clozapine Intoxication: Case Report and Discussion","volume":"46","author":"Cranshaw","year":"2020","journal-title":"Schizophr. Bull."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/13\/12\/439\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:40:47Z","timestamp":1760179247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/13\/12\/439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,2]]},"references-count":127,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["ph13120439"],"URL":"https:\/\/doi.org\/10.3390\/ph13120439","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,2]]}}}